성감염증(STD) 진단 시장 - 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Sexually Transmitted Diseases (STD) Diagnostics Market [Type of Diagnostic Test: Molecular Test, Serologic Test, Point of Care Test, and Others (Immunological Test etc.)] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

US $ 5,795 ￦ 8,598,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 13,049,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 17,500,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

성감염증(STD)진단 시장 - 조사 범위

TMR의 조사 보고서 "세계의 성감염증(STD) 진단 시장"은 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회도 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지의 세계 성감염증(STD) 진단 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 성감염증(STD) 진단 시장의 연평균 성장률(CAGR%)도 제시합니다.

이 보고서는 광범위한 1차 조사, KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰, 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 성감염증(STD) 진단 시장을 파악하기 위한 2차 조사를 통해 작성되었습니다. 성감염증(STD) 진단 시장을 파악하기 위해 주요 기업의 제품 자료, 연례 보고서, 보도자료 등을 참고했습니다.

시장 현황
2023년 시장 규모	71억 달러
2034년 시장 규모	159억 달러
CAGR	7.6%

이 보고서는 세계 성감염증(STD) 진단 시장의 경쟁 환경을 조사했습니다. 세계 성감염증(STD) 진단 시장에서 사업을 운영하는 주요 업체들이 확인되었으며, 각 업체는 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등 세계 성감염증(STD) 진단 시장에서 활동하는 주요 업체들이 이 보고서에 소개되어 있습니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 서론
• 개요
• 시장 역학
• 세계 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

제6장 세계 시장 분석과 예측 : 진단 검사 유형별

• 서론과 정의
• 주요 조사 결과/ 진전
• 시장 매출 예측 : 진단 검사 유형별, 2020-2034년
  • 분자 검사
  • 혈청학적 검사
  • POC(Point of Care) 검사
  • 기타(면역학적 검사 등)
• 진단 검사 유형별 시장의 매력

제7장 세계 시장 분석과 예측 : 질환별

• 서론과 정의
• 주요 조사 결과/ 진전
• 시장 매출 예측 : 질환 유형별, 2020-2034년
  • 클라미디아
  • 임질
  • 매독
  • HIV/에이즈
  • 인유두종바이러스(HPV)
  • 성기 헤르페스
  • 기타 성감염증
• 질병 유형별 시장의 매력

제8장 세계 시장 분석과 예측 : 최종사용자별

• 서론과 정의
• 주요 조사 결과/ 진전
• 시장 매출 예측 : 최종사용자별, 2020-2034년
  • 병원 및 클리닉
  • 진단 실험실
  • 기타(연구기관, 홈케어 시설 등)
• 최종사용자별 시장의 매력

제9장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 매출 예측 : 지역별
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 국가/지역별 시장의 매력

제10장 북미 시장 분석과 예측

• 미국
• 캐나다

제11장 유럽 시장 분석과 예측

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 기타 유럽

제12장 아시아태평양 시장 분석과 예측

• 중국
• 인도
• 일본
• 호주 및 뉴질랜드
• 기타 아시아태평양

제13장 라틴아메리카 시장 분석과 예측

• 브라질
• 멕시코
• 기타 라틴아메리카

제14장 중동 및 아프리카 시장 분석과 예측

• GCC 국가
• 남아프리카공화국
• 기타 중동 및 아프리카

제15장 경쟁 구도

• 시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
• 시장 점유율 분석 기업별(2023년)
• 기업 개요
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Hologic Inc.
  • Creative Diagnostics
  • Abbott Laboratories
  • Quest Diagnostics
  • BD
  • QIAGEN
  • Cepheid
  • bioMerieux

LSH

영문 목차

영문목차

Sexually Transmitted Diseases (STD) Diagnostics Market - Scope of Report

TMR's report on the global sexually transmitted diseases (STD) diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global sexually transmitted diseases (STD) diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global sexually transmitted diseases (STD) diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the sexually transmitted diseases (STD) diagnostics market.

Market Snapshot
Market Value in 2023	US$ 7.1 Bn
Market Value in 2034	US$ 15.9 Bn
CAGR	7.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global sexually transmitted diseases (STD) diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global sexually transmitted diseases (STD) diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global sexually transmitted diseases (STD) diagnostics market.

The report delves into the competitive landscape of the global sexually transmitted diseases (STD) diagnostics market. Key players operating in the global sexually transmitted diseases (STD) diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global sexually transmitted diseases (STD) diagnostics market profiled in this report.

Key Questions Answered in Global sexually transmitted diseases (STD) diagnostics Market Report:

• What is the sales/revenue generated by sexually transmitted diseases (STD) diagnostics across all regions during the forecast period?
• What are the opportunities in the global sexually transmitted diseases (STD) diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Sexually Transmitted Diseases (STD) Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global sexually transmitted diseases (STD) diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global sexually transmitted diseases (STD) diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global sexually transmitted diseases (STD) diagnostics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sexually Transmitted Diseases (STD) Diagnostics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, 2020-2034

5. Key Insights

• 5.1. Key Product & Brand Analysis
• 5.2. Porter's Five Forces Analysis
• 5.3. CDC's 2022 Sexually Transmitted Disease (STI) Surveillance
• 5.4. Insights on Sexually Transmitted Infections in Low and Middle Income Countries

6. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Type of Diagnostic Test

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Type of Diagnostic Test, 2020-2034
  • 6.3.1. Molecular Test
  • 6.3.2. Serologic Test
  • 6.3.3. Point of Care Test
  • 6.3.4. Others (Immunological Test etc.)
• 6.4. Market Attractiveness By Type of Diagnostic Test

7. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Disease Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Disease Type, 2020-2034
  • 7.3.1. Chlamydia
  • 7.3.2. Gonorrhea
  • 7.3.3. Syphilis
  • 7.3.4. HIV/AIDS
  • 7.3.5. Human Papillomavirus (HPV)
  • 7.3.6. Genital Herpes
  • 7.3.7. Others STDs
• 7.4. Market Attractiveness By Disease Type

8. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By End-user, 2020-2034
  • 8.3.1. Hospitals & Clinics
  • 8.3.2. Diagnostic Laboratories
  • 8.3.3. Others (Research Institutes, Homecare Settings etc.)
• 8.4. Market Attractiveness By End-user

9. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Country/Region

10. North America Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
  • 10.2.1. Molecular Test
  • 10.2.2. Serologic Test
  • 10.2.3. Point of Care Test
  • 10.2.4. Others (Immunological Test etc.)
• 10.3. Market Value Forecast By Disease Type, 2020-2034
  • 10.3.1. Chlamydia
  • 10.3.2. Gonorrhea
  • 10.3.3. Syphilis
  • 10.3.4. HIV/AIDS
  • 10.3.5. Human Papillomavirus (HPV)
  • 10.3.6. Genital Herpes
  • 10.3.7. Others STDs
• 10.4. Market Value Forecast By End-user, 2020-2034
  • 10.4.1. Hospitals & Clinics
  • 10.4.2. Diagnostic Laboratories
  • 10.4.3. Others (Research Institutes, Homecare Settings etc.)
• 10.5. Market Value Forecast By Country, 2020-2034
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Type of Diagnostic Test
  • 10.6.2. By Disease Type
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
  • 11.2.1. Molecular Test
  • 11.2.2. Serologic Test
  • 11.2.3. Point of Care Test
  • 11.2.4. Others (Immunological Test etc.)
• 11.3. Market Value Forecast By Disease Type, 2020-2034
  • 11.3.1. Chlamydia
  • 11.3.2. Gonorrhea
  • 11.3.3. Syphilis
  • 11.3.4. HIV/AIDS
  • 11.3.5. Human Papillomavirus (HPV)
  • 11.3.6. Genital Herpes
  • 11.3.7. Others STDs
• 11.4. Market Value Forecast By End-user, 2020-2034
  • 11.4.1. Hospitals & Clinics
  • 11.4.2. Diagnostic Laboratories
  • 11.4.3. Others (Research Institutes, Homecare Settings etc.)
• 11.5. Market Value Forecast By Country, 2020-2034
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Type of Diagnostic Test
  • 11.6.2. By Disease Type
  • 11.6.3. By End-user
  • 11.6.4. By Country

12. Asia Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
  • 12.2.1. Molecular Test
  • 12.2.2. Serologic Test
  • 12.2.3. Point of Care Test
  • 12.2.4. Others (Immunological Test etc.)
• 12.3. Market Value Forecast By Disease Type, 2020-2034
  • 12.3.1. Chlamydia
  • 12.3.2. Gonorrhea
  • 12.3.3. Syphilis
  • 12.3.4. HIV/AIDS
  • 12.3.5. Human Papillomavirus (HPV)
  • 12.3.6. Genital Herpes
  • 12.3.7. Others STDs
• 12.4. Market Value Forecast By End-user, 2020-2034
  • 12.4.1. Hospitals & Clinics
  • 12.4.2. Diagnostic Laboratories
  • 12.4.3. Others (Research Institutes, Homecare Settings etc.)
• 12.5. Market Value Forecast By Country, 2020-2034
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Type of Diagnostic Test
  • 12.6.2. By Disease Type
  • 12.6.3. By End-user
  • 12.6.4. By Country

13. Latin America Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
  • 13.2.1. Molecular Test
  • 13.2.2. Serologic Test
  • 13.2.3. Point of Care Test
  • 13.2.4. Others (Immunological Test etc.)
• 13.3. Market Value Forecast By Disease Type, 2020-2034
  • 13.3.1. Chlamydia
  • 13.3.2. Gonorrhea
  • 13.3.3. Syphilis
  • 13.3.4. HIV/AIDS
  • 13.3.5. Human Papillomavirus (HPV)
  • 13.3.6. Genital Herpes
  • 13.3.7. Others STDs
• 13.4. Market Value Forecast By End-user, 2020-2034
  • 13.4.1. Hospitals & Clinics
  • 13.4.2. Diagnostic Laboratories
  • 13.4.3. Others (Research Institutes, Homecare Settings etc.)
• 13.5. Market Value Forecast By Country, 2020-2034
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Type of Diagnostic Test
  • 13.6.2. By Disease Type
  • 13.6.3. By End-user
  • 13.6.4. By Country

14. Middle East & Africa Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
  • 14.2.1. Molecular Test
  • 14.2.2. Serologic Test
  • 14.2.3. Point of Care Test
  • 14.2.4. Others (Immunological Test etc.)
• 14.3. Market Value Forecast By Disease Type, 2020-2034
  • 14.3.1. Chlamydia
  • 14.3.2. Gonorrhea
  • 14.3.3. Syphilis
  • 14.3.4. HIV/AIDS
  • 14.3.5. Human Papillomavirus (HPV)
  • 14.3.6. Genital Herpes
  • 14.3.7. Others STDs
• 14.4. Market Value Forecast By End-user, 2020-2034
  • 14.4.1. Hospitals & Clinics
  • 14.4.2. Diagnostic Laboratories
  • 14.4.3. Others (Research Institutes, Homecare Settings etc.)
• 14.5. Market Value Forecast By Country, 2020-2034
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Type of Diagnostic Test
  • 14.6.2. By Disease Type
  • 14.6.3. By End-user
  • 14.6.4. By Country

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2023)
• 15.3. Company Profiles
  • 15.3.1. F. Hoffmann-La Roche Ltd
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Hologic Inc.
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Creative Diagnostics
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Abbott Laboratories
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Quest Diagnostics
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview
  • 15.3.7. BD
    • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. SWOT Analysis
    • 15.3.7.5. Strategic Overview
  • 15.3.8. QIAGEN
    • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. SWOT Analysis
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Cepheid
    • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. SWOT Analysis
  • 15.3.10. bioMerieux
    • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. Financial Overview
    • 15.3.10.4. SWOT Analysis
    • 15.3.10.5. Strategic Overview

관련자료